Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Half of people with worse liver function responded well to immunotherapy.
Researchers analyzed the immunological mechanisms that may drive this difference.
This is according to the large randomized controlled START trial.
Weight-based Harvoni treatment cured almost almost all of a small group of very young people.
One researcher argues that the pharmaceutical industry ought to pay greater heed to such risks during drug development.
Among those who switched their hep B treatment, Vemlidy may also be tied to a higher chance of ALT liver enzyme normalization.
A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.
In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.
This is according to the largest-ever analysis of the treatment cascade among people tested for hep C.
Whether such recurrence is less likely after interferon treatment remains the source of some controversy in the hep C research community.
Preliminary results from an ongoing trial found that half of the participants could take less than 12 weeks of a cure regimen.
Liver fat may be a driver of increased cancer risk associated with obesity.
A second immunotherapy option is now available for hepatocellular carcinoma.
Preterm delivery is defined as giving birth before 37 weeks of gestation.
Investigators have found biomarkers that might one day be used to help detect liver cancer during earlier stages.
Treating hep C lowers the risk.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.